Ping Hu
Hematology/Oncology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 24
- 5 carriers
- Office
- 1
Offices
1 location · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
24 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Ping Hu’s office at (408) 885-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
24 of 24 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A128681 · Current
Licensed to practise in California · since 2014 · expires 2027-03-31 · Capital University of Medical Sciences.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$29,368
Medicare paid this office $29,368 for 175 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 122 | $17,852 | $78 |
| New patient visit (45+ min) | 41 | $4,284 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,350 | $71 |
| Telephone medical discussion with physician, 21-30 minutes | 18 | $1,324 | $70 |
Who their Medicare patients are
175 Original Medicare patients in 2024. Average age 72 · Under 65 12% · 85 and older 11% · Women 46% · Also on Medicaid 83% · Health risk score 2.12. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 69% · Cancer 36% · Diabetes 33% · Chronic kidney disease 25% · Heart failure 22% · Atrial fibrillation 18% · Depression 17% · COPD 15% · Coronary heart disease 14% · Stroke 10% · Dementia 7%.
The office billed $257,979, Medicare allowed $40,951 and paid $29,368; for 349 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 175 | 349 | 72 | 2.12 | $257,979 | $29,368 |
| 2023 | 164 | 346 | 72 | 1.97 | $252,003 | $28,821 |
| 2022 | 167 | 411 | 71 | 1.91 | $271,030 | $34,839 |
| 2021 | 168 | 449 | 71 | 2.56 | $242,506 | $42,046 |
| 2020 | 162 | 403 | 71 | 2.44 | $200,578 | $25,664 |
| 2019 | 165 | 347 | 70 | 1.95 | $236,665 | $24,825 |
| 2018 | 156 | 305 | 69 | 1.71 | $207,800 | $20,246 |
| 2017 | 74 | 194 | 69 | 2.00 | $118,336 | $12,675 |
| 2016 | 52 | 276 | 67 | 2.00 | $70,721 | $10,793 |
| 2015 | 219 | 11,177 | 71 | 2.51 | $355,481 | $155,608 |
| 2014 | 85 | 1,661 | 74 | 2.40 | $78,341 | $34,404 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Return visit (30+ min) | 125 | $19,593 | $77 |
| New patient visit (45+ min) | 26 | $2,821 | $109 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $2,189 | $73 |
2022: 3 services
| Return visit (30+ min) | 112 | $18,576 | $89 |
| Telephone medical discussion with physician, 21-30 minutes | 88 | $9,124 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $4,415 | $100 |
2021: 6 services
| Telephone medical discussion with physician, 21-30 minutes | 118 | $25,722 | $94 |
| Return visit (30+ min) | 46 | $5,206 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $3,841 | $101 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 17 | $1,865 | $110 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,722 | $144 |
| Telephone medical discussion with physician, 5-10 minutes | 16 | $570 | $34 |
2020: 6 services
| Telephone medical discussion with physician, 11-20 minutes | 98 | $7,556 | $46 |
| Return visit (30+ min) | 63 | $4,561 | $57 |
| Telephone medical discussion with physician, 21-30 minutes | 40 | $3,296 | $70 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 15 | $3,192 | $106 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,400 | $133 |
| Telephone medical discussion with physician, 5-10 minutes | 24 | $651 | $22 |
2019: 2 services
| Return visit (30+ min) | 138 | $19,062 | $67 |
| New patient visit (45+ min) | 42 | $4,437 | $106 |
2018: 2 services
| Return visit (30+ min) | 135 | $16,503 | $63 |
| New patient visit (45+ min) | 32 | $3,213 | $100 |
2017: 2 services
| Return visit (30+ min) | 64 | $10,996 | $65 |
| New patient visit (45+ min) | 13 | $1,337 | $103 |
2016: 1 service
| Return visit (30+ min) | 49 | $9,580 | $63 |
2015: 16 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 79 | $26,122 | $89 |
| Return visit (30+ min) | 57 | $11,264 | $86 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $10,927 | $171 |
| Administration of chemotherapy into vein, 1 hour or less | 15 | $5,396 | $123 |
| New patient visit (60+ min) | 27 | $4,173 | $155 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 15 | $2,466 | $62 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 21 | $1,812 | $27 |
| Administration of chemotherapy into vein, each additional hour | 13 | $1,330 | $25 |
| Injection of additional new drug or substance into vein | 14 | $605 | $20 |
| Injection of drug or substance under skin or into muscle | 12 | $518 | $23 |
| Insertion of needle into vein for collection of blood sample | 63 | $347 | $3 |
| Injection, granisetron hydrochloride, 100 mcg | 16 | $211 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 14 | $59 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 15 | $27 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 20 | $26 | None |
| Infusion, normal saline solution, 250 cc | 23 | $15 | None |
2014: 7 services
| Return visit (30+ min) | 19 | $3,493 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $3,056 | $170 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $2,608 | $87 |
| New patient visit (60+ min) | 14 | $2,448 | $175 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 12 | $532 | $27 |
| Insertion of needle into vein for collection of blood sample | 37 | $150 | $3 |
| Injection, diphenhydramine hcl, up to 50 mg | 11 | $7 | None |
Medicaid work
$13,772 in 2024
Medicaid paid $13,772 for 1,891 billed services this clinician did in 2024, up to 85 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 703 | $11,641 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 44 | $1,261 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 35 | $862 |
| Short return visit (20+ min) | 12 | $7 |
| Medication list documented in medical record (COA) | 378 | $0 |
| Review of all medications by a prescribing practitioner or clinical pharmacist (such as, prescriptions, OTCs, herbal therapies and supplements) documented in the medical record (COA) | 269 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 180 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 14 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 22 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 204 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 30 | $0 |
| 2024 | 1,891 | 11 | 85 | $13,772 |
| 2023 | 1,004 | 6 | 106 | $8,062 |
| 2022 | 786 | 4 | 80 | $11,562 |
| 2021 | 1,052 | 5 | 67 | $11,518 |
| 2020 | 588 | 7 | 57 | $6,886 |
| 2019 | 875 | 7 | 70 | $3,909 |
| 2018 | 893 | 6 | 69 | $6,189 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 857 | $6,837 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 56 | $762 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 13 | $256 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 16 | $199 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 14 | $7 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 48 | $0 |
2022
| Return visit (30+ min) | 621 | $9,499 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 36 | $794 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 81 | $706 |
| COMPREHENSIVE METABOLIC PANEL | 48 | $562 |
2021
| Return visit (30+ min) | 554 | $6,298 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 308 | $2,603 |
| COMPREHENSIVE METABOLIC PANEL | 148 | $1,755 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 28 | $469 |
| Short return visit (20+ min) | 14 | $393 |
2020
| Return visit (30+ min) | 208 | $2,097 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 156 | $1,204 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 35 | $1,199 |
| COMPREHENSIVE METABOLIC PANEL | 73 | $856 |
| 1ST HOSP IP/OBS SF/LOW 40 | 44 | $556 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 29 | $510 |
| Short return visit (20+ min) | 43 | $464 |
2019
| Return visit (30+ min) | 582 | $1,856 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 133 | $1,146 |
| Basic metabolic panel (Calcium, total) This panel must include the following: Calcium, total (82310) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Potassium (84132) Sodium (84295) Urea nitrogen (BUN) (84520) | 37 | $345 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 14 | $250 |
| HEPATIC FUNCTION PANEL | 76 | $157 |
| New patient visit (45+ min) | 13 | $155 |
| Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes | 20 | $0 |
2018
| Return visit (30+ min) | 537 | $3,425 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 132 | $1,111 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 55 | $958 |
| Basic metabolic panel (Calcium, total) This panel must include the following: Calcium, total (82310) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Potassium (84132) Sodium (84295) Urea nitrogen (BUN) (84520) | 49 | $460 |
| HEPATIC FUNCTION PANEL | 108 | $235 |
| New patient visit (45+ min) | 12 | $0 |
Drugs they prescribed that Part D paid
$1,519,503
Pharmacies billed $1,519,503 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
393 generic and fewer than 11 brand-name prescriptions · $1,519,503 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 21 | $276,263 | $13,155 |
| Calquence | 11 | $154,061 | $14,006 |
| Abiraterone Acetate | 39 | $96,741 | $2,481 |
| Lonsurf | 12 | $90,063 | $7,505 |
| Imatinib Mesylate | 17 | $51,986 | $3,058 |
See all 20 drugs
| Xtandi | 21 | $276,263 | $13,155 |
| Calquence | 11 | $154,061 | $14,006 |
| Abiraterone Acetate | 39 | $96,741 | $2,481 |
| Lonsurf | 12 | $90,063 | $7,505 |
| Imatinib Mesylate | 17 | $51,986 | $3,058 |
| Eliquis | 36 | $33,467 | $930 |
| Venclexta | 14 | $19,785 | $1,413 |
| Aprepitant | 30 | $14,523 | $484 |
| Everolimus | 11 | $13,078 | $1,189 |
| Xarelto | 14 | $7,535 | $538 |
| Hydroxyurea | 19 | $478 | $25 |
| Ondansetron Odt | 17 | $409 | $24 |
| Anastrozole | 25 | $335 | $13 |
| Prednisone | 54 | $259 | $5 |
| Letrozole | 12 | $183 | $15 |
| Acyclovir | 19 | $180 | $9 |
| Loperamide | 13 | $180 | $14 |
| Omeprazole | 21 | $151 | $7 |
| Allopurinol | 21 | $149 | $7 |
| Ondansetron | 25 | $147 | $6 |
Year by year
| 2024 | 552 | 101 | None | None | $1,519,503 |
| 2023 | 613 | 94 | None | None | $1,720,658 |
| 2022 | 515 | 86 | None | 28% | $1,624,468 |
| 2021 | 541 | 87 | 3% (14) | None | $1,898,160 |
| 2020 | 570 | 88 | 4% (22) | 37% | $2,050,164 |
| 2019 | 542 | 92 | 4% (24) | 30% | $1,384,506 |
| 2018 | 324 | 81 | 3% (11) | 23% | $664,893 |
| 2017 | 148 | 44 | None | 24% | $223,526 |
| 2016 | 250 | 71 | 5% (13) | None | $302,215 |
| 2015 | 558 | 126 | 9% (49) | 22% | $703,200 |
| 2014 | 148 | 59 | 18% (27) | 32% | $190,503 |
| 2013 | 81 | 26 | 15% (12) | 42% | $180,206 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Xtandi | 27 | $405,080 | $15,003 |
| Ibrance | 13 | $230,081 | $17,699 |
| Lenalidomide | 12 | $186,176 | $15,515 |
| Tagrisso | 11 | $173,532 | $15,776 |
| Abiraterone Acetate | 28 | $126,978 | $4,535 |
| Imatinib Mesylate | 25 | $76,135 | $3,045 |
| Venclexta | 11 | $32,553 | $2,959 |
| Eliquis | 28 | $25,198 | $900 |
| Xarelto | 19 | $14,974 | $788 |
| Aprepitant | 11 | $6,453 | $587 |
| Dabigatran Etexilate | 21 | $6,343 | $302 |
| Hydroxyurea | 28 | $1,657 | $59 |
| Anastrozole | 31 | $915 | $30 |
| Doxycycline Monohydrate | 19 | $912 | $48 |
| Ondansetron Odt | 21 | $471 | $22 |
| Loperamide | 20 | $464 | $23 |
| Ondansetron | 29 | $397 | $14 |
| Allopurinol | 16 | $377 | $24 |
| Prednisone | 43 | $369 | $9 |
| Omeprazole | 14 | $266 | $19 |
| Dexamethasone | 18 | $232 | $13 |
2022: 17 drugs
| Revlimid | 31 | $485,069 | $15,647 |
| Xtandi | 34 | $391,068 | $11,502 |
| Ibrance | 14 | $209,328 | $14,952 |
| Imatinib Mesylate | 27 | $107,763 | $3,991 |
| Tafinlar | 14 | $97,043 | $6,932 |
| Abiraterone Acetate | 15 | $12,416 | $828 |
| Pradaxa | 11 | $5,683 | $517 |
| Hydroxyurea | 24 | $909 | $38 |
| Ondansetron | 24 | $905 | $38 |
| Ondansetron Odt | 19 | $637 | $34 |
| Bicalutamide | 18 | $496 | $28 |
| Loperamide | 19 | $425 | $22 |
| Anastrozole | 22 | $406 | $18 |
| Prednisone | 27 | $237 | $9 |
| Acyclovir | 15 | $208 | $14 |
| Allopurinol | 12 | $179 | $15 |
| Omeprazole | 12 | $57 | $5 |
2021: 18 drugs
| Revlimid | 30 | $503,874 | $16,796 |
| Lenvima | 17 | $344,495 | $20,264 |
| Xtandi | 32 | $329,757 | $10,305 |
| Ibrance | 13 | $181,829 | $13,987 |
| Imatinib Mesylate | 25 | $46,370 | $1,855 |
| Xarelto | 11 | $12,247 | $1,113 |
| Abiraterone Acetate | 14 | $6,886 | $492 |
| Letrozole | 18 | $1,338 | $74 |
| Hydroxyurea | 30 | $881 | $29 |
| Dexamethasone | 45 | $819 | $18 |
| Ondansetron Odt | 24 | $732 | $31 |
| Anastrozole | 28 | $559 | $20 |
| Bicalutamide | 11 | $469 | $43 |
| Prednisone | 24 | $301 | $13 |
| Loperamide | 11 | $265 | $24 |
| Duloxetine | 13 | $189 | $15 |
| Omeprazole | 29 | $148 | $5 |
| Ondansetron | 12 | $126 | $10 |
2020: 20 drugs
| Xtandi | 53 | $575,443 | $10,857 |
| Revlimid | 40 | $511,021 | $12,776 |
| Ibrance | 13 | $173,171 | $13,321 |
| Imatinib Mesylate | 13 | $24,112 | $1,855 |
| Xarelto | 19 | $16,720 | $880 |
| Letrozole | 19 | $1,346 | $71 |
| Dexamethasone | 35 | $856 | $24 |
| Tamoxifen Citrate | 11 | $546 | $50 |
| Hydroxyurea | 16 | $544 | $34 |
| Ondansetron Odt | 24 | $487 | $20 |
| Anastrozole | 25 | $471 | $19 |
| Acyclovir | 13 | $348 | $27 |
| Prochlorperazine Maleate | 14 | $276 | $20 |
| Prednisone | 13 | $234 | $18 |
| Loperamide | 16 | $218 | $14 |
| Oxycodone | 11 | $142 | $13 |
| Duloxetine | 13 | $116 | $9 |
| Omeprazole | 24 | $100 | $4 |
| Allopurinol | 14 | $100 | $7 |
| Ondansetron | 11 | $72 | $7 |
2019: 17 drugs
| Revlimid | 25 | $335,300 | $13,412 |
| Xtandi | 25 | $274,901 | $10,996 |
| Jakafi | 11 | $137,719 | $12,520 |
| Xarelto | 26 | $18,592 | $715 |
| Tamoxifen Citrate | 17 | $768 | $45 |
| Acyclovir | 15 | $753 | $50 |
| Dexamethasone | 34 | $712 | $21 |
| Ondansetron Odt | 24 | $607 | $25 |
| Hydroxyurea | 12 | $561 | $47 |
| Loperamide | 32 | $527 | $16 |
| Prochlorperazine Maleate | 38 | $463 | $12 |
| Anastrozole | 19 | $450 | $24 |
| Prednisone | 11 | $152 | $14 |
| Ondansetron | 21 | $131 | $6 |
| Allopurinol | 13 | $80 | $6 |
| Omeprazole | 14 | $73 | $5 |
| Hydrocortisone | 11 | $62 | $6 |
2018: 8 drugs
| Xtandi | 17 | $180,195 | $10,600 |
| Gilotrif | 11 | $84,253 | $7,659 |
| Hydroxyurea | 13 | $698 | $54 |
| Dexamethasone | 26 | $326 | $13 |
| Ondansetron Odt | 15 | $298 | $20 |
| Anastrozole | 12 | $291 | $24 |
| Prochlorperazine Maleate | 20 | $173 | $9 |
| Ondansetron | 17 | $163 | $10 |
2017: 4 drugs
| Xtandi | 17 | $169,411 | $9,965 |
| Tamoxifen Citrate | 12 | $587 | $49 |
| Hydroxyurea | 12 | $461 | $38 |
| Prednisone | 11 | $157 | $14 |
2016: 6 drugs
| Zytiga | 12 | $96,656 | $8,055 |
| Anastrozole | 19 | $748 | $39 |
| Hydroxyurea | 17 | $512 | $30 |
| Bicalutamide | 12 | $350 | $29 |
| Prednisone | 19 | $221 | $12 |
| Dexamethasone | 14 | $73 | $5 |
2015: 22 drugs
| Gleevec | 21 | $255,561 | $12,170 |
| Tarceva | 13 | $88,518 | $6,809 |
| Enoxaparin | 13 | $10,492 | $807 |
| Anastrozole | 45 | $1,576 | $35 |
| Fluconazole | 16 | $1,014 | $63 |
| Polyethylene Glycol 3350 | 32 | $944 | $30 |
| Morphine Sulfate Er | 14 | $679 | $49 |
| Levofloxacin | 20 | $580 | $29 |
| Doxycycline Hyclate | 12 | $577 | $48 |
| Ondansetron | 14 | $566 | $40 |
| Tamoxifen Citrate | 18 | $453 | $25 |
| Hydroxyurea | 18 | $353 | $20 |
| Morphine Sulfate | 13 | $338 | $26 |
| Hydrocodone-Acetaminophen | 14 | $280 | $20 |
| Allopurinol | 16 | $254 | $16 |
| Omeprazole | 19 | $251 | $13 |
| Prochlorperazine Maleate | 13 | $195 | $15 |
| Acyclovir | 12 | $188 | $16 |
| Prednisone | 16 | $180 | $11 |
| Dexamethasone | 12 | $107 | $9 |
| Gabapentin | 14 | $91 | $7 |
| Potassium Chloride | 13 | $56 | $4 |
2014: 2 drugs
| Gleevec | 12 | $111,108 | $9,259 |
| Anastrozole | 13 | $462 | $36 |
Money from drug and device companies
$26 in 2022
| 2022 | 1 | 2 | None | $26 |
| 2021 | 2 | 4 | None | $52 |
| 2019 | 1 | 1 | None | $12 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Acrotech Biopharma | Beleodaq | $26 | 2 payments
|
See all 2 published payments
| Acrotech Biopharma | Education · 2022-03-03 | Beleodaq | $14 |
| Acrotech Biopharma | Education · 2022-01-06 | Beleodaq | $12 |
See earlier years (2021, 2019)
2021: $52
| Acrotech Biopharma | Beleodaq | $40 | 3 payments
|
| Gilead Sciences | None | $12 | 1 payment
|
2019: $12
| Seattle Genetics | Adcetris | $12 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1982867297
- Licence
- CA A128681California A128681: Current · expires 2027-03-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 5 Harris Ct Bldg T #201, Monterey, CA, 93940
- NPI first listed
- 2008-07-07
- NPI last updated
- 2018-02-02
This is when the NPI record was last certified, not a medical board exam.